{"entity":{"id":"nct06567015","kind":"trial","name":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","aka":[],"tldr":"A phase 1/2 trial of STX-241 in non-small-cell lung cancer, run by Pierre Fabre Medicament, now recruiting.","summary":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs is a phase 1/2 interventional study registered as NCT06567015 by Pierre Fabre Medicament, with 171 participants planned, started 2024-09-17 and due to reach its primary completion in 2027-11-20. Interventions recorded: STX-241.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06567015","url":"https://clinicaltrials.gov/study/NCT06567015"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06567015","phase":"1/2","setting":"Phase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).","sponsor":"Pierre Fabre Medicament","started":"2024-09-17","startedType":"actual","enrolled":171,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06567015/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}]}}